WO1996018391B1 - Use of mono and bicarboxylic acid amides for the manufacture of a medicament active at the peripheral cannabinoid receptor - Google Patents

Use of mono and bicarboxylic acid amides for the manufacture of a medicament active at the peripheral cannabinoid receptor

Info

Publication number
WO1996018391B1
WO1996018391B1 PCT/EP1995/004927 EP9504927W WO9618391B1 WO 1996018391 B1 WO1996018391 B1 WO 1996018391B1 EP 9504927 W EP9504927 W EP 9504927W WO 9618391 B1 WO9618391 B1 WO 9618391B1
Authority
WO
WIPO (PCT)
Prior art keywords
use according
diseases
pathologies
disease
mono
Prior art date
Application number
PCT/EP1995/004927
Other languages
French (fr)
Other versions
WO1996018391A2 (en
WO1996018391A3 (en
Inventor
Valle Francesco Della
Alberta Leon
Gabriele Marcolongo
Silvana Lorenzi
Original Assignee
Lifegroup Spa
Valle Francesco Della
Alberta Leon
Gabriele Marcolongo
Silvana Lorenzi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lifegroup Spa, Valle Francesco Della, Alberta Leon, Gabriele Marcolongo, Silvana Lorenzi filed Critical Lifegroup Spa
Priority to JP51826596A priority Critical patent/JP4216330B2/en
Priority to AU43442/96A priority patent/AU4344296A/en
Priority to US08/860,356 priority patent/US5990170A/en
Priority to CA002207850A priority patent/CA2207850C/en
Priority to EP95942142A priority patent/EP0799033A1/en
Publication of WO1996018391A2 publication Critical patent/WO1996018391A2/en
Publication of WO1996018391A3 publication Critical patent/WO1996018391A3/en
Publication of WO1996018391B1 publication Critical patent/WO1996018391B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The following description concerns the therapeutic use of amidic derivatives of mono and bicarboxylic acids with aminoalcohols or aminoethers in the manufacture of a medicament for the treatment of diseases connected with the modulation of the cannabinoid peripheral receptor, said amidic derivatives being selectively active on said receptor.

Claims

-84-
AMENDED CLAIMS
[received by the International Bureau on 15 July 1996 ( 15.07.96); original claims 30 and 31 amended; remaining claims unchanged (1 page)]
system selected from multiple sclerosis and amyotrophic lateral sclerosis. 26. The use according to claim 1, characterised in that said diseases are pathologies connected with the immune system alteration. 27. The use according to claim 1, characterised in that said diseases are pathologies involving pressure alterations at cardiovascular, polmunary or ocular level. 28. The use according to claim 27, characterised in that said diseases involving pressure alterations are glaucoma or cephalea. 29. The use according to claim 1, characterised in that said disease is nausea. 30. The use according to claim 1, characterised in that said diseases are pathologies caused by biological agents, selected from the group consisting of viral (HIV) and bacterial encephalitic meningitis, bacterial meningitis and meningitis by cytomegalovirus. 31- The use according to claim 1, characterised in that said disease is cachetic symptomatology associated with chronic degenerative pathologies selected from the group consisting of senile dementia, Alzheimer' s and Parkinson' s diseases. 32. The use according to claim 1, characterised in that said diseases are cardiovascular pathologies associated with vascular remodelling, atherosclerosis or heart attack. 33> The use according to claim 1, characterised in that said disease is chronic airway obstruction.
PCT/EP1995/004927 1994-12-14 1995-12-13 Use of mono and bicarboxylic acid amides for the manufacture of a medicament active at the peripheral cannabinoid receptor WO1996018391A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP51826596A JP4216330B2 (en) 1994-12-14 1995-12-13 Use of mono- and bicarboxylic amides in the manufacture of drugs acting at peripheral cannabinoid receptors
AU43442/96A AU4344296A (en) 1994-12-14 1995-12-13 Use of mono and bicarboxylic acid amides for the manufacture of a medicament active at the peripheral cannabinoid receptor
US08/860,356 US5990170A (en) 1994-12-14 1995-12-13 Therapeutic use of mono and bicarboxylic acid amides active at the peripheral cannabinoid receptor
CA002207850A CA2207850C (en) 1994-12-14 1995-12-13 Use of mono and bicarboxylic acid amides for the manufacture of a medicament active at the peripheral cannabinoid receptor
EP95942142A EP0799033A1 (en) 1994-12-14 1995-12-13 Use of mono and bicarboxylic acid amides for the manufacture of a medicament active at the peripheral cannabinoid receptor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI942512A IT1271266B (en) 1994-12-14 1994-12-14 THERAPEUTIC USE OF MONO AND BICARBOXYLIC ACID AMIDES WITH AMINO ALCOHOLS, SELECTIVELY ACTIVE ON THE PERIPHERAL RECEPTOR OF CANNABINOIDS
ITMI94A002512 1994-12-14

Publications (3)

Publication Number Publication Date
WO1996018391A2 WO1996018391A2 (en) 1996-06-20
WO1996018391A3 WO1996018391A3 (en) 1996-08-15
WO1996018391B1 true WO1996018391B1 (en) 2001-04-05

Family

ID=11369989

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1995/004927 WO1996018391A2 (en) 1994-12-14 1995-12-13 Use of mono and bicarboxylic acid amides for the manufacture of a medicament active at the peripheral cannabinoid receptor

Country Status (8)

Country Link
US (1) US5990170A (en)
EP (1) EP0799033A1 (en)
JP (1) JP4216330B2 (en)
AU (1) AU4344296A (en)
CA (1) CA2207850C (en)
IL (1) IL116400A0 (en)
IT (1) IT1271266B (en)
WO (1) WO1996018391A2 (en)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19706903A1 (en) * 1997-02-21 1998-08-27 Bayer Ag Use of known agonists of the central cannabinoid receptor CB 1
WO1999060987A2 (en) * 1998-05-29 1999-12-02 Neurosciences Research Foundation, Inc. Control of pain with endogenous cannabinoids
IT1302264B1 (en) 1998-09-24 2000-09-05 Innovet Italia Srl DERIVATIVES WITH N-ACYL VANILLYAMIDE STRUCTURE ABLE TO ACTIVATE PERIPHERAL IRECEPTORS OF CANNABINOIDS
US6566560B2 (en) 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
US6864285B1 (en) 1999-07-07 2005-03-08 Innovet Italia S.R.L. Covalent derivatives of alkanolamides of monocarboxylic and dicarboxylic acids functionally active on the CB2 cannabinoid receptor
EP1207870B1 (en) * 1999-08-06 2005-03-16 Innovet Italia S.r.l. Pharmaceutical compositions containing n-palmitoylethanolamide and use thereof in the veterinary field
FR2800372B1 (en) * 1999-11-03 2001-12-07 Sanofi Synthelabo TRICYCLIC DERIVATIVES OF 1-BENZYLPYRAZOLE-3- CARBOXYLIC ACID, THEIR PREPARATION, THE MEDICINAL PRODUCTS CONTAINING THEM
US6410597B1 (en) * 2000-02-25 2002-06-25 Virginia Commonwealth University Hydroxyalkyl amide analogs of ceramide
WO2001089589A1 (en) * 2000-05-23 2001-11-29 The Regents Of The University Of California A novel treatment for cough
AU2002213429A1 (en) * 2000-09-28 2002-04-08 Immugen Pharmaceuticals, Inc. Antiviral methods and compounds
AU2001296402A1 (en) * 2000-09-28 2002-04-08 Immugen Pharmaceuticals, Inc. Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation
US7067539B2 (en) * 2001-02-08 2006-06-27 Schering Corporation Cannabinoid receptor ligands
US7507767B2 (en) * 2001-02-08 2009-03-24 Schering Corporation Cannabinoid receptor ligands
US7025992B2 (en) * 2001-02-14 2006-04-11 Gw Pharma Limited Pharmaceutical formulations
GB0104268D0 (en) * 2001-02-21 2001-04-11 Unilever Plc Antiperspirant or deodorant compositions
TWI238068B (en) 2001-03-06 2005-08-21 Kao Corp Composition for external application
US6911474B2 (en) * 2001-03-27 2005-06-28 The Regents Of The University Of California Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism
WO2002079139A1 (en) 2001-03-29 2002-10-10 Basf Aktiengesellschaft Conjugated unsaturated glyceride mixtures and a method for producing the same
CN1788722A (en) * 2001-05-23 2006-06-21 钱吉子 Composition for preventing or treating dementia
ITMI20011483A1 (en) * 2001-07-11 2003-01-11 Res & Innovation Soc Coop A R USE OF COMPOUNDS AS FUNCTIONAL ANTAGONISTS TO CENTRAL DEICANNABINOID RECEPTORS
ATE374011T1 (en) * 2001-07-18 2007-10-15 Unilever Nv SKIN TREATMENT PRODUCTS
EP1406576B2 (en) * 2001-07-18 2011-06-29 Unilever PLC Hair and/or scalp treatment compositions
TWI250023B (en) * 2001-10-22 2006-03-01 Santen Pharmaceutical Co Ltd Pharmaceutical composition for itch treating agent
NZ532291A (en) 2001-11-14 2005-11-25 Schering Corp Cannabinoid receptor ligands
AU2002357114B2 (en) * 2001-12-07 2008-07-24 Virginia Commonwealth University Treatment of neoplasia
EP1477186B1 (en) 2002-02-19 2009-11-11 Shionogi & Co., Ltd. Antipruritics
US7351729B2 (en) 2002-03-08 2008-04-01 Signal Pharmaceuticals, Llc JNK inhibitors for use in combination therapy for treating or managing proliferative disorders and cancers
NZ534757A (en) 2002-03-12 2006-07-28 Merck & Co Inc Substituted amides
AU2003214226A1 (en) * 2002-03-18 2003-10-08 Immugen Pharmaceuticals, Inc. Topical formulations of resorcinols and cannibinoids and methods of use
UA79281C2 (en) * 2002-04-03 2007-06-11 Solvay Pharm Bv Stabilized composition comprising a natural cannabinoid compound and process for the preparation thereof
AU2003243637A1 (en) 2002-06-19 2004-01-06 Schering Corporation Cannabinoid receptor agonists
US20040018151A1 (en) * 2002-07-26 2004-01-29 Abood Mary E. Use of anandamide/cannabinoid receptor/acceptor agonists in als screening and treatment methods
AR042120A1 (en) 2002-11-25 2005-06-08 Schering Corp CANNABINOID RECEIVING LINKS
TW200505902A (en) * 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
BRPI0411740A (en) 2003-06-26 2006-05-23 Takeda Pharmaceutical cannabinoid receptor modulator, compound, prodrug, drug, method for preventing or treating a disease or condition, use of a compound, and method for preparing a compound
US7193096B2 (en) 2003-07-01 2007-03-20 Loders Croklaan Usa Llc Process for producing a conjugated di- or poly-unsaturated fatty acid of 12 to 24 carbon atoms or salt or ester thereof
US7750158B2 (en) * 2004-06-22 2010-07-06 Schering Corporation Cannabinoid receptor ligands
EA200701246A1 (en) * 2004-12-09 2008-06-30 Инсис Терапьютикс, Инк. STABLE UNDER ROOM TEMPERATURE COMPOSITIONS OF DRONABINOL
JPWO2008111296A1 (en) 2007-03-09 2010-06-24 国立大学法人京都大学 Pharmaceuticals for the prevention and treatment of skin diseases caused by increased keratinization
IL187247A0 (en) * 2007-11-08 2008-12-29 Hadasit Med Res Service Novel synthetic analogs of sphingolipids
EP2262763A2 (en) * 2008-03-04 2010-12-22 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Compounds and methods of treating obesity
EP2174642A1 (en) * 2008-10-10 2010-04-14 Unilever Plc, A Company Registered In England And Wales under company no. 41424 of Unilever House Use of Personal Care Composition
WO2011009883A1 (en) 2009-07-23 2011-01-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Selective cb2 receptor agonists for use in the prevention or treatment of alcoholic liver disease
ES2548190T3 (en) * 2009-09-07 2015-10-14 Epitech Group S.P.A. Composition containing ultramicronized palmitoylethanolamide
CN102229527B (en) 2009-12-14 2016-05-04 脂质营养品有限公司 Process
US10019119B2 (en) 2010-09-09 2018-07-10 3M Innovative Properties Company Touch sensitive device with stylus support
ES2603809T3 (en) 2014-03-19 2017-03-01 Epitech Group S.R.L. Pharmaceutical composition comprising palmitoylethanolamide and L-acetylcarnitine
ES2731729T3 (en) 2014-05-14 2019-11-18 Epitech Group S P A Use of palmitoylethanolamide in combination with opioids
ES2641143T3 (en) 2014-08-13 2017-11-07 Epitech Group S.P.A. A pharmaceutical composition comprising palmitoylethanolamide and cytidine diphosphocoline
JP7041673B2 (en) * 2016-10-13 2022-03-24 カーノット， エルエルシー N-Acylethanolamide Derivatives and Their Use
MY186286A (en) 2017-09-05 2021-07-05 Frimline Private Ltd A pharmaceutical composition for improving or preventing progression of chronic kidney disease
IT202000007831A1 (en) 2020-04-14 2021-10-14 Epitech Group S P A ADELMIDROL FOR USE IN THE TREATMENT OF LUNG FIBROSIS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1252866B (en) * 1991-12-31 1995-06-28 Lifegroup Spa N-ACYL DERIVATIVES OF AMINOALCOHOLS WITH POLYCARBOSSYLIC ACIDS FOR THE MODULATION OF MASTOCYTES IN INFLAMMATORY PROCESSES ON A NEURO-IMMUNOGENIC BASIS
IT1252865B (en) * 1991-12-31 1995-06-28 Lifegroup Spa N-ACYL DERIVATIVES OF AMINOALCOHOLS ACTIVE AS LOCAL AUTOCOIDS AND USABLE IN THE THERAPY OF AUTOIMMUNE PROCESSES
IT1271623B (en) * 1994-03-21 1997-06-04 Lifegroup Spa N-ACYL DERIVATIVES OF AMINO-ALCOHOLS WITH MONOCARBOSSYL AND BICARBOSSYLIC ACIDS WITH NEUROPROTECTIVE ACTIVITY IN NEUROLOGICAL DISEASES RELATED TO EXCITOTOXICITY

Also Published As

Publication number Publication date
ITMI942512A0 (en) 1994-12-14
CA2207850C (en) 2009-08-04
US5990170A (en) 1999-11-23
WO1996018391A2 (en) 1996-06-20
WO1996018391A3 (en) 1996-08-15
IL116400A0 (en) 1996-03-31
CA2207850A1 (en) 1996-06-20
JPH11500411A (en) 1999-01-12
ITMI942512A1 (en) 1996-06-14
JP4216330B2 (en) 2009-01-28
EP0799033A1 (en) 1997-10-08
IT1271266B (en) 1997-05-27
AU4344296A (en) 1996-07-03

Similar Documents

Publication Publication Date Title
WO1996018391B1 (en) Use of mono and bicarboxylic acid amides for the manufacture of a medicament active at the peripheral cannabinoid receptor
AU9125798A (en) Specific saccharide compositions and methods for treating alzheimer's disease and other amyloidoses
RU2002133098A (en) THERAPEUTIC COMBINATIONS OF FATTY ACIDS
EP1645634A3 (en) Transgenic animal models for cardiac hypertrophy and uses thereof
WO2000078322A3 (en) Combination of lactic acid bacteria and its use for the prevention and/or treatment of infections and inflammatory conditions
JP2004501969A5 (en)
GB2302329B (en) Yeast strains
TNSN99135A1 (en) NEUROPROTECTIVE COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF NERVOUS OR BEHAVIORAL DISORDERS DUE TO ANXIETY OR DEPRESSION
WO2000043354A3 (en) Multicyclic compounds which inhibit leukocyte adhesion mediated by vla-4
TW197423B (en)
AU7556994A (en) Methods for the diagnosis of alzheimer's disease
JP2003534282A5 (en)
ES2108595A1 (en) 3(2H)-pyridazinone derivatives and process for the preparation thereof
AU5053296A (en) Pharmaceutical agents for the treatment of Alzheimer's disease
AU1458495A (en) Application of riluzole in the treatment of mitochondrial diseases
EP1216702A3 (en) Aminotetralin derivative for the therapy of cardiovascular diseases
AU5911590A (en) Pharmaceutical and dietary uses of fatty acids
USD454954S1 (en) Medical diagnostic ultrasound system
EP0305277A3 (en) Use of 2-amino-6-trifluoromethoxybenzothiazole for the preparation of a medicament for the treatment of sleep disorders and depression
EP0679394A3 (en) Menatetronome derivative as antiarteriosclerotic agent
AU7076494A (en) Utilization of efaroxan and derivatives thereof for the preparation of a medicament intended to the treatment of parkinson disease
WO1995025509A3 (en) Use of n-acyl derivatives of aminoalcohols in the manufacture of a medicament for practising neuroprotective action in neuropathological states connected with excitotoxicity
CA2065889A1 (en) Increasing the choroidal blood flow
CA2135752A1 (en) Use of (E)-2-(p-Fluorophenethyl)-3-Fluoroallylamine in the Treatment of Alzheimer's Disease
Feigal Protease inhibitors and beyond: interview with David Feigal, MD Interview by John S James

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AU BB BG BR BY CA CN CZ EE FI GE HU IS JP KE KG KP KR KZ LK LR LS LT LV MD MG MK MN MW MX NO NZ PL RO RU SD SG SI SK TJ TM TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AU BB BG BR BY CA CN CZ EE FI GE HU IS JP KE KG KP KR KZ LK LR LS LT LV MD MG MK MN MW MX NO NZ PL RO RU SD SG SI SK TJ TM TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2207850

Country of ref document: CA

Ref country code: CA

Ref document number: 2207850

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: JP

Ref document number: 1996 518265

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1995942142

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 08860356

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1995942142

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995942142

Country of ref document: EP

AK Designated states

Kind code of ref document: B1

Designated state(s): AL AM AU BB BG BR BY CA CN CZ EE FI GE HU IS JP KE KG KP KR KZ LK LR LS LT LV MD MG MK MN MW MX NO NZ PL RO RU SD SG SI SK TJ TM TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: B1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG